Akero Therapeutics — Technical Presentation (January 2025)
22 slides from Akero Therapeutics's technical presentation, Jan 27, 2025
Slide 1: Topline Preliminary Week 96 Results From Phase 2b SYMMETRY Study
Topline Preliminary Week 96 Results From Phase 2b SYMMETRY Study in Patients with Compensated Cirrhosis (F4) Due to MASH January 27, 2025 Restoring balance. Renewing Life. Exhibit 99.2
Slide 2: Safe Harbor and Legal Disclaimers
Safe Harbor and Legal Disclaimers This presentation may contain “forward-looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial condit
Slide 3: High Risk of Mortality Associated with Cirrhosis Due to MASH
High Risk of Mortality Associated with Cirrhosis Due to MASH Survival Free of Liver Transplantation Follow-up (years) Cumulative Survival (%) Angulo, P et al. (2015) Gastroenterology 149:389-397 P<0.001 F4 50% ~50% 5-year mortality without liver transplant for F4 patients 40% 20% 0% 100% 80% 60% ©20
Slide 4: No Compound To Date Has Shown Statistically Significant Reversal of Cirrhosis Due to MASH
1mg (n=42) 3mg (n=55) 21% 15% No Compound To Date Has Shown Statistically Significant Reversal of Cirrhosis Due to MASH in Clinical Trials 6mg (n=351 18mg (n=354) 20mg (n=37) 40mg (n=39) 14% 13% 31% 24% 25mg (n~306) 10mg (n~306) 10% 12% 2.4mg (n=47) 11% 200mg (n=76) 700mg (n=79) 8% 8% Aldafermin5 48
Slide 5: Phase 2b SYMMETRY Trial Design: Compensated Cirrhosis (F4) Due to MASH
Phase 2b SYMMETRY Trial Design: Compensated Cirrhosis (F4) Due to MASH with Liver Histology at 36 and 96 weeks EFX 28mg (N=57) Placebo (N=61) EFX 50mg (N=63) Screening Randomization Phase 2b Key Inclusion Criteria1 F4 MASH, Child-Pugh A T2D or 2 of 4 components of metabolic syndrome2 Phase 2b Primar
Slide 6: Baseline Demographics
Baseline Demographics Parameter (Mean) Placebo (N=61) EFX 28mg (N=57) EFX 50mg (N=63) Age (Years) 61 62 59 Sex (% Female) 62 68 70 Enhanced Liver Fibrosis (ELF) Score 10.4 10.6 10.5 Liver Stiffness by VCTE (FibroScan) (kPa) 24.7 24.1 24.5 Alanine Aminotransferase (ALT) (U/L) 40.3 40.1 38.4 Aspartate
Slide 7: Patient Disposition
11% Discontinued for Administrative Reasons1 Patient Disposition 28mg (N=41) (89% Retention) 50mg (N=46) (90% Retention) Placebo (N=47) (82% Retention) Biopsy Collected at Week 36 (N=154) Randomized & Dosed (N=181) Biopsy Collected at Week 96 (N=134) 87% Retained from Week 36 to 96 2% Discontinued D
Slide 8: SYMMETRY Week 96 Main Analysis Sets
SYMMETRY Week 96 Main Analysis Sets Analysis Set1 N Description Week 96 Liver Biopsy Analysis Set (LBAS) 134 All patients with baseline and Week 96 biopsy results Safety Set / Full Analysis Set (FAS)2 181 All randomized patients who received at least one dose of study drug 28mg (N=41) 50mg (N=46) Pl
Slide 9: Unprecedented Reversal of Cirrhosis Observed in SYMMETRY with 50mg EFX
Placebo (N=61) EFX 28mg (N=57) EFX 50mg (N=63) 12% 21% *29%* EFX 28mg N=41 EFX 50mg N=46 Placebo N=47 Fibrosis Improvement ≥1 Stage & No Worsening of MASH at Week 96 Primary Analysis1 1 All patients with baseline and Week 96 biopsies ** p<0.01, versus placebo (CMH test3) ** 39%** 29% 15% Unprecedent
Slide 10: Improved and Durable Response Observed with Longer Treatment
Sustained (n=6) New (n=6) Sustained (n=9) New (n=9) Sust. (n=4) New (n=3) **39%** EFX 28mg N=41 EFX 50mg N=46 Placebo N=47 29% 15% Fibrosis Improvement ≥1 Stage & No Worsening of MASH at Week 96 Sustained1 & New2 Responders Placebo (N=8) EFX 28mg (N=9) EFX 50mg (N=12) 4 (50%) 6 (67%) 9 (75%) Proport
Slide 11: Baseline GLP-1 Therapy Did Not Impact Reversal of Cirrhosis
EFX 28mg N=32 EFX 50mg N=29 Placebo N=36 **45%** 28% 17% Subgroup (N=97): Patients Without GLP-1 Use at Baseline EFX 28mg N=41 EFX 50mg N=46 Placebo N=47 ** p<0.01, versus placebo (CMH test) **39%** 29% 15% All Patients with Baseline and Week 96 Biopsies (N=134) Baseline GLP-1 Therapy Did Not Impact
Slide 12: MASH Resolution Observed at Week 96
EFX 28mg N=32 EFX 50mg N=40 Placebo N=34 MASH Resolution Primary Analysis1 ** p<0.01, *** p<0.001, versus placebo (CMH test) **55%** ***59%*** 18% MASH Resolution Observed at Week 96 Source Data: LBAS subgroup (definitive MASH at baseline); FAS ©2025 AKERO THERAPEUTICS. Placebo (N=45) EFX 28mg (N=45
Slide 13: Treatment-Emergent Adverse Events Through Week 96
Treatment-Emergent Adverse Events (TEAEs): Cumulative from Baseline through Week 96 TEAE Overview Placebo (N=61) EFX 28mg (N=57) EFX 50mg (N=63) TEAEs Leading to Death a 1 (2%) a 0 (0%) 0 (0%) Treatment-Emergent Serious Adverse Events (SAEs) 11 (18%) 15 (26%) 15 (24%) Drug-Related SAEs 0 0 0 TEAEs L
Slide 14: Additional Safety Observations for 50mg EFX Versus Placebo at Week 96
Additional Safety Observations for 50mg EFX (Phase 3 Dose) Versus Placebo at Week 96 Bone Mineral Density 43% of 50mg EFX and 41% of placebo patients had osteopenia1 at baseline, but only 3% of 50mg EFX and 7% of placebo patients were treated with bisphosphonates Placebo-adjusted, significant relati
Slide 15: Reductions in Imaging and Circulating Biomarkers of Fibrosis
Pattern of Reductions in Imaging and Circulating Biomarkers of Fibrosis Corroborate Histological Improvement in Cirrhosis LS Mean Change From Baseline to Week 96 Source Data: FAS (non-missing values only, no imputation) ©2025 AKERO THERAPEUTICS. Liver Stiffness (%)2 -18% -8% EFX 50mg N=47 Placebo N=
Slide 16: Reductions in Markers of Liver Injury Sustained Through Week 96
(Baseline: 38-40 U/L) * p<0.05,** p<0.01, *** p<0.001, versus placebo (MMRM) Statistically Significant Reductions in Markers of Liver Injury Sustained Through Week 96 with 50mg EFX ALT (U/L) LS Mean Change from Baseline AST (U/L) LS Mean Change from Baseline *** * * ** * ** ** ** ** * ** ** ** *** *
Slide 17: Significantly Improved Lipoprotein Profile Observed at Week 96
EFX 50mg N=47 Placebo N=49 EFX 28mg N=40 HDL Cholesterol **+6** -2 ***+9*** ** p<0.01, *** p<0.001, versus placebo (MMRM) EFX 50mg N=47 Placebo N=49 EFX 28mg N=40 Non-HDL Cholesterol -19 -10 -21* EFX 50mg N=47 Placebo N=49 EFX 28mg N=40 Triglycerides *-27* -3 *-33* * p<0.05, *versus placebo (MMRM) S
Slide 18: Significantly Improved Insulin Sensitivity Observed at Week 96
EFX 50mg N=45 Placebo N=48 EFX 28mg N=41 C-Peptide (%) * p<0.05, versus placebo (MMRM) -13% -1% *-18%* EFX 50mg N=46 Placebo N=49 EFX 28mg N=41 Adiponectin (%) +32% +8% ***69%*** *** p<0.001, versus placebo (MMRM) Significantly Improved Insulin Sensitivity Observed at Week 96 with 50mg EFX Source Da
Slide 19: EFX is the First Compound Reported to Statistically Significantly Reverse Cirrhosis Due to MASH
Aldafermin5 48 Wks / Ph2b Discontinued FGF19 1mg (n=42) 3mg (n=55) 21% 15% EFX is the First Compound that Has Been Reported to Statistically Significantly Reverse Cirrhosis Due to MASH1 Selonsertib3 48 Wks / Ph3 Discontinued ASK-1 Peg-FGF21 Pegbelfermin4 48 Wks / Ph2b Discontinued 6mg (n=351 18mg (n
Slide 20: Phase 3 SYNCHRONY Outcomes Trial Design
Phase 3 SYNCHRONY Outcomes Trial Design Baseline Liver Biopsy EFX 50mg Placebo Total Treatment Duration: ~260 Weeks Week 96 Liver Biopsy (Cohort 1) Patient Population Cirrhosis Due to MASH (F4, Compensated) Primary Histology Endpoint ≥ 1-stage fibrosis improvement and no worsening of MASH at Week 96
Slide 21: Unprecedented Clinical Activity for 50mg EFX After 96 Weeks
Unprecedented Clinical Activity for 50mg EFX After 96 Weeks ©2024 AKERO THERAPEUTICS. Completers 39% vs. 15% (24% Effect Size) Source Data: LBAS; ITT ITT 29% vs. 12% (17% Effect Size) Reversal of Cirrhosis in <2 Years p=0.009 p=0.031 With Favorable Tolerability Profile ≥1 stage improvement in fibros
Slide 22: Akero Therapeutics, South San Francisco, CA
AKERO THERAPEUTICS 601 Gateway Boulevard Suite 350 South San Francisco, CA 94080 Nasdaq: AKRO
Akero Therapeutics — Technical Presentation (January 2025) on 6ix